Demircan, M.B.; Mgbecheta, P.C.; Kresinsky, A.; Schnoeder, T.M.; Schröder, K.; Heidel, F.H.; Böhmer, F.D.
Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells. Antioxidants 2022, 11, 513.
https://doi.org/10.3390/antiox11030513
AMA Style
Demircan MB, Mgbecheta PC, Kresinsky A, Schnoeder TM, Schröder K, Heidel FH, Böhmer FD.
Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells. Antioxidants. 2022; 11(3):513.
https://doi.org/10.3390/antiox11030513
Chicago/Turabian Style
Demircan, Muhammed Burak, Peter C. Mgbecheta, Anne Kresinsky, Tina M. Schnoeder, Katrin Schröder, Florian H. Heidel, and Frank D. Böhmer.
2022. "Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells" Antioxidants 11, no. 3: 513.
https://doi.org/10.3390/antiox11030513
APA Style
Demircan, M. B., Mgbecheta, P. C., Kresinsky, A., Schnoeder, T. M., Schröder, K., Heidel, F. H., & Böhmer, F. D.
(2022). Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells. Antioxidants, 11(3), 513.
https://doi.org/10.3390/antiox11030513